Teladoc Health, INC Form 4 insider transactions

Director Mark Douglas Smith acquired 17,467 restricted stock units in Teladoc Health, Inc. on May 23, 2024.

Director Thomas McKinley reports acquisition of 17,467 restricted stock units and conversion of 9,834 restricted stock units into common stock.

Director Karen Daniel converted restricted stock units and sold shares of Teladoc Health (TDOC) common stock on May 22 and 23, 2024, according to a recent SEC filing.

Director Catherine Jacobson reports exercising stock options and acquiring restricted stock units in Teladoc Health, Inc.

Daniel Trencher, Chief Strategy Officer of Teladoc Health, sold 1,000 shares of common stock at a price of $12.83 per share on May 17, 2024, according to a Form 4 filing with the SEC.

Laizer Kornwasser, President of Enterprise Growth at Teladoc Health, reports the acquisition and disposal of company stock related to restricted stock units.

Michael Waters, COO of Teladoc Health, reports the acquisition and disposal of company stock related to restricted stock units.

Vidya Raman-Tangella, Chief Medical Officer of Teladoc Health, sold shares to cover tax obligations related to vesting restricted stock units.

Daniel Trencher, Chief Strategy Officer of Teladoc Health, sold 1,000 shares of common stock on April 17, 2024, at a price of $13.21 per share.

Mala Murthy, Acting CEO and CFO of Teladoc Health, acquired 37,957 restricted stock units on April 5, 2024, according to a Form 4 filing with the SEC.

Nikolaos P. Nanis, Chief Technology Officer of Teladoc Health, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Teladoc Health's Chief People Officer, Arnnon Geshuri, exercised stock options and sold shares on March 25, 2024, according to a recent SEC filing.

Teladoc Health's Chief Marketing Officer, Stephany Verstraete, was granted 46,700 restricted stock units (RSUs) on March 19, 2024, according to a recent SEC filing.

Teladoc Health's CFO, Mala Murthy, reported the acquisition of 110,800 restricted stock units (RSUs) on March 19, 2024.

Teladoc Health's CEO, Jason Gorevic, acquired 197,728 restricted stock units on March 19, 2024, according to a recent SEC filing.

Nikolaos P. Nanis, Chief Technology Officer of Teladoc Health, acquired 37,900 restricted stock units on March 19, 2024, according to a recent SEC filing.

Daniel Trencher, Chief Strategy Officer of Teladoc Health, reports the acquisition of 40,800 restricted stock units.

Andrew Turitz, EVP of Corporate Development at Teladoc Health, reports the acquisition of 43,800 restricted stock units (RSUs) in a recent SEC filing.

Arnnon Geshuri, Chief People Officer of Teladoc Health, recently acquired 40,800 restricted stock units (RSUs) representing a contingent right to receive one share of TDOC common stock.

Richard J. Napolitano, Chief Accounting Officer of Teladoc Health, Inc., reported the acquisition of 37,500 restricted stock units on March 19, 2024, according to a Form 4 filing with the SEC.

Teladoc Health's President of Enterprise Growth, Kornwasser Laizer, reported acquiring 102,100 restricted stock units on March 19, 2024.

Vidya Raman-Tangella, Chief Medical Officer of Teladoc Health, acquired 35,000 restricted stock units on March 19, 2024.

Teladoc Health's Chief Operating Officer, Michael Willem Waters, was granted 87,500 restricted stock units (RSUs) on March 19, 2024, according to a Form 4 filing with the SEC.

Adam C. Vandervoort, Chief Legal Officer and Secretary of Teladoc Health, reports the acquisition of 64,200 restricted stock units (RSUs) on March 19, 2024.

Daniel Trencher, Chief Strategy Officer of Teladoc Health, sold 1,000 shares of common stock on March 18, 2024, at a price of $15.18 per share.

Andrew Turitz, EVP of Corporate Development at Teladoc Health, sold 5,647 shares of common stock at $14.53 per share on March 5, 2024, under a pre-arranged 10b5-1 trading plan.

Laizer Kornwasser, President of Enterprise Growth at Teladoc Health, reports the acquisition and disposal of Teladoc Health common stock and derivative securities.

Richard J. Napolitano, Chief Accounting Officer of Teladoc Health, reports transactions involving common stock and derivative securities, including acquisitions and disposals related to performance and restricted stock units.

Teladoc Health's Chief Operating Officer, Michael Willem Waters, reports the acquisition and disposal of common stock and derivative securities, including performance stock units and restricted stock units.

Stephany Verstraete, Chief Marketing Officer of Teladoc Health, reports acquisition and disposal of common stock and derivative securities, including performance stock units and restricted stock units.